TYK2 heats up with Ventyx eyeing mid-stage trials; NexImmune cites competition in pipeline cull
Ventyx said it will begin testing its TYK2 inhibitor in multiple mid-stage clinical trials before the clock strikes 2023.
The news comes just weeks …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
